Navigation Links
Human testis harbors HIV-1 in resident immune cells

Researchers have demonstrated HIV replication within resident immune cells of the testis, providing an explanation for the persistence of virus in semen even after effective highly active antiretroviral therapy. The related report by Roulet et al., “Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro,?appears in the December issue of The American Journal of Pathology.

According to the most recent World Health Organization data, 39.5 million people are infected with HIV. Semen remains the main means of spreading the virus, even though highly active antiretroviral therapy (HAART) can successfully suppress virus in the blood. The presence of HIV in the semen despite successful HAART has intrigued scientists.

Researchers led by Dr. Nathalie Dejucq-Rainsford examined testis tissue for the presence of HIV receptors. They found that all of the necessary cellular receptors (CD4, CXCR4, CCR5, and DC-SIGN) were present on cells located within the testis, specifically testicular macrophages.

The point was demonstrated further by using explanted organ cultures in which human testis tissue was grown in culture. This testis culture, which retained the same tissue architecture as in vivo tissue and continued to secrete testosterone, was able to support infection by HIV-1. Virus produced from the testis culture was fully active as collected virus was able to infect permissive cells in culture.

The finding that HIV-1 can replicate within testicular macrophages is significant because the testis represents a pharmacological sanctuary—many anti-retroviral drugs have difficulty penetrating this organ and may be present at sub-therapeutic levels. Thus, although HAART may achieve undetectable virus levels in the blood, virus replication in the testis may permit continued spread of the virus.

Finally, with HIV infection continuing to rise, the development of anti-retroviral therapy that effectiv ely targets all sources of HIV, including the testis, is gravely needed. The use of this testis culture system may allow assessment of new anti-retroviral drugs that target HIV in the testis.
'"/>

Source:American Journal of Pathology


Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. New Clues Add 40,000 Years to Age of Human Species
3. Human Cells Filmed Instantly Messaging for First Time
4. Govt Creates Gene Database of Normal Human Tissues
5. Analysis Of Human Genome To Predict The Development Of Illnesses
6. Human Eggs Can Develop From Ovarian Surface Cells In Vitro
7. Determining The Fate Of Cells In The Human Body
8. Whole genome promoter mapping - Human Genome Project v2.0?
9. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
10. Going To Extremes To Improve Human Health
11. Human brain is still evolving

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology: